Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,806.40
(
0.76%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.53
(
0.33%
)
Bitcoin
81,407.92
(
0.43%
)
News Focus
News Focus
Post# of 50165
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

RainyDayWriter

Send PM Follow Ignore
Followers 3
Posts 1176
Boards Moderated 0
Alias Born 03/02/2018

RainyDayWriter

Re: RainyDayWriter post# 47928

Wednesday, 03/06/2019 12:24:34 AM

Wednesday, March 06, 2019 12:24:34 AM

Post# of 50165
Continued from previous post:

July, 2017 (continued)

Delcath Systems (OTC:DCTH) is an interventional oncology company focusing on the treatment of liver cancer. It is still doing trials on its Melblez Kit filter system that was failed to be approved by the FDA way back in 2013. The stock is up 1000% over the past month on no news, just recently created hype. The stock closed yesterday at $0.18, reached over $0.30 on June 21st, and was trading between $0.02-$0.04 between May 11th and June 8th.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent DCTH News
More DCTH News